212 related articles for article (PubMed ID: 22903389)
1. Pharmacological effects of cannabinoids on the reference and working memory functions in mice.
Avdesh A; Hoe Y; Martins RN; Martin-Iverson MT
Psychopharmacology (Berl); 2013 Jan; 225(2):483-94. PubMed ID: 22903389
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats.
Braida D; Sala M
Neuroreport; 2000 Jun; 11(9):2025-9. PubMed ID: 10884065
[TBL] [Abstract][Full Text] [Related]
3. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
4. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
5. CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations.
Basavarajappa BS; Subbanna S
Hippocampus; 2014 Feb; 24(2):178-88. PubMed ID: 24123667
[TBL] [Abstract][Full Text] [Related]
6. Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
Hruba L; McMahon LR
J Pharmacol Exp Ther; 2017 Aug; 362(2):278-286. PubMed ID: 28533288
[TBL] [Abstract][Full Text] [Related]
7. Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol.
Wise LE; Thorpe AJ; Lichtman AH
Neuropsychopharmacology; 2009 Aug; 34(9):2072-80. PubMed ID: 19322169
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
McMahon LR; Ginsburg BC; Lamb RJ
Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
[TBL] [Abstract][Full Text] [Related]
9. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.
Fattore L; Spano S; Cossu G; Deiana S; Fadda P; Fratta W
Neuropharmacology; 2005 Jun; 48(8):1097-104. PubMed ID: 15910886
[TBL] [Abstract][Full Text] [Related]
11. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
12. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.
Haller J; Varga B; Ledent C; Freund TF
Behav Pharmacol; 2004 Jul; 15(4):299-304. PubMed ID: 15252281
[TBL] [Abstract][Full Text] [Related]
13. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
[TBL] [Abstract][Full Text] [Related]
14. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats.
Lichtman AH
Eur J Pharmacol; 2000 Sep; 404(1-2):175-9. PubMed ID: 10980277
[TBL] [Abstract][Full Text] [Related]
15. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid modulation of rat pup ultrasonic vocalizations.
McGregor IS; Dastur FN; McLellan RA; Brown RE
Eur J Pharmacol; 1996 Oct; 313(1-2):43-9. PubMed ID: 8905327
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant.
Paquette JJ; Wang HY; Bakshi K; Olmstead MC
Behav Pharmacol; 2007 Dec; 18(8):767-76. PubMed ID: 17989514
[TBL] [Abstract][Full Text] [Related]
18. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
19. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
Lichtman AH; Martin BR
Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
[TBL] [Abstract][Full Text] [Related]
20. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats.
Lichtman AH; Dimen KR; Martin BR
Psychopharmacology (Berl); 1995 Jun; 119(3):282-90. PubMed ID: 7675962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
